Peer-reviewed veterinary case report
Predicting doxorubicin drug levels in dogs with fewer blood samples
By Wittenburg, L A et al.·Published in Veterinary and comparative oncology·2014·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.
- Species:
- dog
Plain-English summary
A study focused on dogs receiving doxorubicin, a common chemotherapy drug for cancer treatment, aimed to improve how veterinarians predict the drug's effects. By taking just three blood samples within an hour after treatment, the researchers found they could accurately estimate how much of the drug was in the dog's system. This new method could help vets adjust dosages more effectively, ensuring that each dog gets the right amount of medication while minimizing side effects like low blood cell counts.
People also search for: dog cancer treatment doxorubicin · chemotherapy side effects in dogs · how to monitor dog cancer medication
Abstract
Understanding the relationship between drug dose and exposure (pharmacokinetics, PK) and the relationship between exposure and effect (pharmacodynamics) is an important component of pharmacology when attempting to predict clinical effects of anticancer drugs. PK studies can provide a better understanding of these relationships; however, they often involve intensive sampling over an extended period of time, resulting in increased cost and decreased compliance. Doxorubicin (DOX), one of the most widely used antineoplastic agents in veterinary cancer therapy, is characterized by large interpatient variability in overall drug exposure and the development and degree of myelosuppression following equivalent dosages. We have developed and validated a limited-sampling strategy for DOX, in which three blood samples are obtained over 1 h post-treatment, that accurately predicts patient exposure. This strategy could allow for refining of dosing variables and utilization of therapeutic drug monitoring to ensure optimized dosing.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22747489/